Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chemotherapy Clear all
Completed Early Phase 1 Interventional

Autologous OC-DC Vaccine in Ovarian Cancer

NCT01132014
View directory record Official record
Conditions
Chemotherapy, Tumor, Ovarian Cancer
Interventions
OCDC
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Jul 22, 2026, 5:55 AM EDT
Recruiting Not applicable Interventional

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy

NCT05990426
View directory record Official record
Conditions
Ovary Cancer, Endometrial Cancer, Uterine Cancer
Interventions
FAST Intervention
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

NCT04301778
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Durvalumab, SNDX-6352
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

NCT01292135
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
PCI-32765
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Boston, Massachusetts • New Hyde Park, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Jul 22, 2026, 5:55 AM EDT
Recruiting Not applicable Interventional

HIIT Following Breast Cancer Chemotherapy

NCT05913713
View directory record Official record
Conditions
Breast Cancer
Interventions
12-week Intervention Period, 12-week Observation Period
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 22, 2026, 5:55 AM EDT
Recruiting Phase 1 Interventional

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma

NCT05141513
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00006721
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin, prednisone, vincristine, tositumomab
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2025
U.S. locations
259
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 167 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional

A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients

NCT00001384
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Adriamycin, cyclophosphamide, G-CSF, paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 5:55 AM EDT
Recruiting No phase listed Observational

VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients

NCT06878547
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrasound
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
20 Years to 90 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

NCT02560025
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Alisertib, Cytarabine, Idarubicin, Daunorubicin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

NCT03029143
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab IV
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
44
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Pablo, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jul 22, 2026, 5:55 AM EDT
Recruiting Phase 2 Interventional

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

NCT06745076
View directory record Official record
Conditions
Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Dacarbazine, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Vinblastine, Questionnaire
Procedure · Drug · Biological + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
6
States / cities
Irvine, California • Palo Alto, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

NCT06290050
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam, Repaglinide, TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Jul 22, 2026, 5:55 AM EDT
Terminated No phase listed Observational Results available

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

NCT02761187
View directory record Official record
Conditions
Multiple Myeloma
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
4,253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
43
States / cities
Little Rock, Arkansas • La Jolla, California • Santa Rosa, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

NCT02124148
View directory record Official record
Conditions
Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer
Interventions
Prexasertib, Cisplatin, Cetuximab, G-CSF, Pemetrexed, Fluorouracil, LY3023414, Leucovorin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Jul 22, 2026, 5:55 AM EDT
Withdrawn Phase 2 Interventional

Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

NCT03901378
View directory record Official record
Conditions
Neuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, High Grade Neuroendocrine Carcinoma, Any Site
Interventions
Pembrolizumab
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Kenner, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00046917
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, irinotecan hydrochloride, cisplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2014 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00045604
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, imatinib mesylate, irinotecan hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2008 · Synced Jul 22, 2026, 5:55 AM EDT
Terminated Early Phase 1 Interventional

Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

NCT02582008
View directory record Official record
Conditions
Current Smoker, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Interventions
Bupropion Hydrochloride, Laboratory Biomarker Analysis, Nicotine Replacement, Quality-of-Life Assessment, Questionnaire Administration, Varenicline
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 22, 2026, 5:55 AM EDT
Not listed Phase 3 Interventional Results available

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

NCT00807768
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy, Internal Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
533
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jul 22, 2026, 5:55 AM EDT
Completed Phase 2 Interventional

Automated Telephone Monitoring for Symptom Management

NCT00799084
View directory record Official record
Conditions
Carcinoma
Interventions
Nurse, AVR
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Jul 22, 2026, 5:55 AM EDT
Recruiting No phase listed Observational

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

NCT06538038
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions
Osimertinib, Osimertinib + Chemotherapy
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
146
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 5:55 AM EDT
Terminated Early Phase 1 Interventional

Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine

NCT00867126
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
pioglitazone hydrochloride, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2018 · Synced Jul 22, 2026, 5:55 AM EDT
Terminated Phase 2 Interventional Results available

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

NCT02592876
View directory record Official record
Conditions
Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Grade 3b, Follicular Lymphoma, Grade 3b
Interventions
denintuzumab mafodotin, rituximab, ifosfamide, carboplatin, etoposide
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Little Rock, Arkansas • Duarte, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jul 22, 2026, 5:55 AM EDT